Search clinical trials for: denagliptin (GW823093)

Total 212 results

Fayoum University
Boehringer Ingelheim

Completed

Contrast Nephropathy in Type 2 Diabetes (VCG4)

Diabetes | Microalbuminuria | Kidney Function Affection Upon Exposure to Radiocontrast

Egypt
Biogen

Terminated

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Diabetes Mellitus, Type 2

Germany, Spain, United States, Canada, Taiwan, Korea, Republic of, Finland, Denmark, France, Japan, Philippines, Vietnam
Boehringer Ingelheim

Completed

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Healthy

Germany
Rabin Medical Center

Terminated

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

Glucose Metabolism Disorders | Respiratory Tract Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | COVID 19 | Coronavirus | Metabolic Disease | Severe Acute Respiratory Syndrome Coronavirus 2 | Sars-CoV2 | Hormones | Hypoglycemic Agents | Incretins | Dipeptidyl-Peptidase IV Inhibitors and other conditions

Israel
EMS

Not yet recruiting

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Type 2 Diabetes Mellitus
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on to Basal Insulin in the Elderly

Diabetes Mellitus, Type 2

United States, New Zealand, Spain, Japan, Finland, Germany, Greece, Romania, South Africa, Denmark, Colombia, Poland, United Kingdom, Mexico, Australia, Belgium, Ireland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Australia, Canada, Denmark, Netherlands, Sweden
Dong Wha Pharmaceutical Co. Ltd.

Completed

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition

Healthy Subjects

Korea, Republic of
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (PRELLIM)

Insulin Resistance | Prediabetic State

Mexico
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin Add-on to Insulin Background Therapy

Diabetes Mellitus, Type 2

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Healthy

Germany
LG Life Sciences

Completed

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (GUARD)

Type 2 DM Patients With Moderate or Severe Renal Impairment

Korea, Republic of
Ministry of Public Health, Argentina
Aix Marseille Université; Instituto de Biología y Medicina Experimental, IBYME...

Unknown

Effect of Linagliptin on TRL Metabolism

Type 2 Diabetes

Argentina
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
Dong Wha Pharmaceutical Co. Ltd.

Completed

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers

Healthy Subjects

Korea, Republic of
National University of Malaysia

Completed

Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

PreDiabetes | Type 2 Diabetes

Malaysia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, India, Israel, Malaysia, Mexico, Philippines, Puerto Rico, Russian Federation, Sri Lanka, Thailand, Ukraine
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine (RESCATHEME)

Insulin Resistance | Prediabetic State | Impaired Glucose Tolerance

Mexico
Northwell Health

Withdrawn

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Diabetes | SGLT-2 Inhibitors | Advanced Glycation End Products
International Bio service

Not yet recruiting

The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers

Healthy Volunteer
Boehringer Ingelheim

Completed

Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Diabetes Mellitus, Type 2

Austria, Greece, Hungary, Japan, Portugal, Romania, Spain
Emory University
American Diabetes Association

Completed

ADA Linagliptin in Long Term Care

Diabetes

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Boehringer Ingelheim

Completed

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Philippines, Romania, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
Boehringer Ingelheim

Completed

Empa/Lina FDC Food Effect Study (Japan)

Healthy

Japan
JW Pharmaceutical

Completed

MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus (ACACIA)

Type 2 Diabetes

Korea, Republic of
Hospital Regional de Alta Especialidad del Bajio

Completed

Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19 (Covid19DPP4i)

Hyperglycemia | Covid19

Mexico
Boehringer Ingelheim
Eli Lilly and Company

Completed

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

Diabetes Mellitus, Type 2

China, Malaysia, Philippines, Vietnam
Medanta, The Medicity, India

Not yet recruiting

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus (EmLina Renal)

Diabetes Mellitus | Kidney Transplant; Complications
AbbVie

Recruiting

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus

United States, Japan, Puerto Rico, Switzerland, Israel, Korea, Republic of, Hungary, New Zealand, Bulgaria, Latvia, Taiwan, Slovakia, Croatia, South Africa, Australia, Poland, Portugal, Spain, Estonia, France, Lithuania, Brazil, Ger... and more
Zhang Lei, MD

Recruiting

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Thrombocytopenia | Antiphospholipid Syndrome | Treatment

China
EMS

Withdrawn

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Type2 Diabetes Mellitus
Shandong Suncadia Medicine Co., Ltd.

Completed

Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy Subjects

Type 2 Diabetes Mellitus

China
Alexandria University

Recruiting

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS)

Egypt
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Healthy

Germany
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Unknown

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes (4T)

Insulin Resistance | Prediabetic State

Mexico
Amsterdam UMC, location VUmc

Completed

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes (RENALIS)

Type 2 Diabetes

Netherlands
Huashan Hospital

Recruiting

Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes

Liver Cirrhosis | Diabetes

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
The Wistar Institute
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Unknown

Reducing Proviral HIV DNA With Interferon-a (BEAT-HIV)

HIV/AIDS | HIV

United States

Search clinical trials for: denagliptin (GW823093)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations